SI9620076B - Stabilni reagenti za pripravo radiofarmacevtikov - Google Patents
Stabilni reagenti za pripravo radiofarmacevtikov Download PDFInfo
- Publication number
- SI9620076B SI9620076B SI9620076A SI9620076A SI9620076B SI 9620076 B SI9620076 B SI 9620076B SI 9620076 A SI9620076 A SI 9620076A SI 9620076 A SI9620076 A SI 9620076A SI 9620076 B SI9620076 B SI 9620076B
- Authority
- SI
- Slovenia
- Prior art keywords
- substituted
- group
- independently selected
- occurrence
- alkyl
- Prior art date
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract 12
- 239000012217 radiopharmaceutical Substances 0.000 title claims abstract 5
- 229940121896 radiopharmaceutical Drugs 0.000 title claims abstract 5
- 230000002799 radiopharmaceutical effect Effects 0.000 title claims abstract 5
- 150000007857 hydrazones Chemical class 0.000 claims abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 229910006069 SO3H Inorganic materials 0.000 claims 5
- 239000003446 ligand Substances 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 101100294118 Caenorhabditis elegans nhr-53 gene Proteins 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000002464 receptor antagonist Substances 0.000 claims 3
- 229940044551 receptor antagonist Drugs 0.000 claims 3
- 101100516569 Caenorhabditis elegans nhr-85 gene Proteins 0.000 claims 2
- 101710091342 Chemotactic peptide Proteins 0.000 claims 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 2
- 150000001723 carbon free-radicals Chemical class 0.000 claims 2
- 239000003638 chemical reducing agent Substances 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 1
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 1
- 102000009123 Fibrin Human genes 0.000 claims 1
- 108010073385 Fibrin Proteins 0.000 claims 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims 1
- 102000003800 Selectins Human genes 0.000 claims 1
- 108090000184 Selectins Proteins 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229950003499 fibrin Drugs 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 1
- 229940075620 somatostatin analogue Drugs 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012216 imaging agent Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 0 CC(C)C(C(N(C)[C@@](CCCNC(*)=N)C(NCC(N[C@](C1)([C@]1C(O)=O)C(NCc1cc2cc(NC(CCCCCNC(c3ccc(NN=C4CCCC4)nc3)=O)=O)c1)=O)=O)=O)=O)NC2=O Chemical compound CC(C)C(C(N(C)[C@@](CCCNC(*)=N)C(NCC(N[C@](C1)([C@]1C(O)=O)C(NCc1cc2cc(NC(CCCCCNC(c3ccc(NN=C4CCCC4)nc3)=O)=O)c1)=O)=O)=O)=O)NC2=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/008—Peptides; Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/476,296 US5750088A (en) | 1993-03-30 | 1995-06-07 | Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals |
| PCT/US1996/009766 WO1996040637A1 (en) | 1995-06-07 | 1996-06-07 | Stable reagents for the preparation of radiopharmaceuticals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SI9620076A SI9620076A (sl) | 1998-08-31 |
| SI9620076B true SI9620076B (sl) | 2000-02-29 |
Family
ID=23891282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI9620076A SI9620076B (sl) | 1995-06-07 | 1996-06-07 | Stabilni reagenti za pripravo radiofarmacevtikov |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US5750088A (2) |
| EP (1) | EP0832068B1 (2) |
| JP (1) | JPH11507364A (2) |
| KR (1) | KR19990022573A (2) |
| CN (1) | CN1192733A (2) |
| AR (1) | AR003959A1 (2) |
| AT (1) | ATE233241T1 (2) |
| AU (1) | AU718683B2 (2) |
| BR (1) | BR9609003A (2) |
| CA (1) | CA2222183A1 (2) |
| CZ (1) | CZ380197A3 (2) |
| DE (1) | DE69626392T2 (2) |
| EA (1) | EA000742B1 (2) |
| EE (1) | EE9700313A (2) |
| ES (1) | ES2193245T3 (2) |
| HR (1) | HRP960250A2 (2) |
| HU (1) | HUP9901469A3 (2) |
| IL (1) | IL118468A0 (2) |
| LT (1) | LT4380B (2) |
| LV (1) | LV12044B (2) |
| MX (1) | MX9709126A (2) |
| MY (1) | MY133974A (2) |
| NO (1) | NO975678L (2) |
| NZ (1) | NZ310799A (2) |
| PL (1) | PL323995A1 (2) |
| SI (1) | SI9620076B (2) |
| SK (1) | SK163497A3 (2) |
| WO (1) | WO1996040637A1 (2) |
| ZA (1) | ZA964854B (2) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0888130B1 (en) * | 1996-03-13 | 2003-07-02 | Bristol-Myers Squibb Pharma Company | New ternary radiopharmaceutical complexes |
| US20030124053A1 (en) * | 1996-10-07 | 2003-07-03 | Barrett John Andrew | Radiopharmaceuticals for imaging infection and inflammation |
| KR20000048922A (ko) * | 1996-10-07 | 2000-07-25 | 블레어 큐. 퍼거슨 | 감염 및 염증의 영상화용 방사성 약제 |
| US6416733B1 (en) | 1996-10-07 | 2002-07-09 | Bristol-Myers Squibb Pharma Company | Radiopharmaceuticals for imaging infection and inflammation |
| US6403054B1 (en) * | 1997-05-28 | 2002-06-11 | Bristol-Myers Squibb Pharma Company | Ternary ligand complexes useful as radiopharmaceuticals |
| US6524553B2 (en) | 1998-03-31 | 2003-02-25 | Bristol-Myers Squibb Pharma Company | Quinolone vitronectin receptor antagonist pharmaceuticals |
| US6537520B1 (en) * | 1998-03-31 | 2003-03-25 | Bristol-Myers Squibb Pharma Company | Pharmaceuticals for the imaging of angiogenic disorders |
| WO1999051628A1 (en) * | 1998-04-03 | 1999-10-14 | Du Pont Pharmaceuticals Company | Radiopharmaceuticals for imaging infection and inflammation and for imaging and treatment of cancer |
| HRP990317A2 (en) * | 1998-10-13 | 2000-06-30 | Du Pont Pharm Co | A process for the preparation of a thrombus imaging agent |
| EP1140864A2 (en) * | 1998-12-18 | 2001-10-10 | Du Pont Pharmaceuticals Company | Vitronectin receptor antagonist pharmaceuticals |
| US6511649B1 (en) | 1998-12-18 | 2003-01-28 | Thomas D. Harris | Vitronectin receptor antagonist pharmaceuticals |
| CA2727746A1 (en) | 1998-12-18 | 2000-06-22 | Bristol-Myers Squibb Pharma Company | Quinolone vitronectin receptor antagonist pharmaceuticals |
| US6794518B1 (en) * | 1998-12-18 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| US6808698B1 (en) | 1999-03-26 | 2004-10-26 | Bristol-Myers Squibb Pharma Company | Method for localization of blood clots |
| BR0010517A (pt) * | 1999-03-26 | 2002-01-08 | Du Pont Pharm Co | Métodos de formação de imagem de um trombo, de um êmbolo pulmonar, de um trombo arterial e de um trombo coronariano |
| US6656448B1 (en) | 2000-02-15 | 2003-12-02 | Bristol-Myers Squibb Pharma Company | Matrix metalloproteinase inhibitors |
| US20030220646A1 (en) * | 2002-05-23 | 2003-11-27 | Thelen Sarah L. | Method and apparatus for reducing femoral fractures |
| US6534038B2 (en) * | 2000-04-07 | 2003-03-18 | Bristol-Myers Squibb Pharma Company | Ternary ligand complexes useful as radiopharmaceuticals |
| AU2002230576A1 (en) * | 2000-11-03 | 2002-05-15 | Bristol-Myers Squibb Pharma Company | Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation |
| GB0031592D0 (en) * | 2000-12-28 | 2001-02-07 | Nycomed Amersham Plc | Stabilised radiopharmaceutical compositions |
| MXPA04001113A (es) * | 2001-08-08 | 2004-07-08 | Bristol Myers Squibb Pharma Co | Formacion de imagenes simultaneas de perfusion cardiaca y agente formador de imagenes dirigido al receptor de vitronectina. |
| US6838074B2 (en) | 2001-08-08 | 2005-01-04 | Bristol-Myers Squibb Company | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent |
| US7297709B2 (en) | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| US7317104B2 (en) | 2003-06-13 | 2008-01-08 | Bristol-Myers Squibb Pharma Company | Chelants and macrocyclic metal complex radiopharmaceuticals thereof |
| US7319149B2 (en) * | 2003-06-13 | 2008-01-15 | Bristol-Myers Squibb Pharma Company | Chelants and macrocyclic metal complex radiopharmaceuticals thereof |
| CA2526556C (en) * | 2003-07-24 | 2012-09-25 | Bracco Imaging S.P.A. | Stable radiopharmaceutical compositions and methods for their preparation |
| US20050106100A1 (en) * | 2003-09-03 | 2005-05-19 | Harris Thomas D. | Compounds containing matrix metalloproteinase substrates and methods of their use |
| WO2007005491A1 (en) * | 2005-06-30 | 2007-01-11 | Bristol-Myers Squibb Pharma Company | Hydrazide conjugates as imaging agents |
| WO2007046411A1 (ja) * | 2005-10-19 | 2007-04-26 | Dainippon Sumitomo Pharma Co., Ltd. | イソキサゾール化合物の安定化方法 |
| AU2006327300A1 (en) * | 2005-12-20 | 2007-06-28 | Astrazeneca Ab | Substituted Cinnoline derivatives as GABAa-receptor modulators and method for their synthesis |
| US7465795B2 (en) * | 2005-12-20 | 2008-12-16 | Astrazeneca Ab | Compounds and uses thereof |
| JP5571387B2 (ja) | 2007-01-11 | 2014-08-13 | クリティカル・アウトカム・テクノロジーズ・インコーポレイテッド | 癌の治療のための化合物および方法 |
| AR067028A1 (es) * | 2007-06-19 | 2009-09-30 | Astrazeneca Ab | Compuestos y usos de los mismos 849 |
| CA2710039C (en) * | 2007-12-26 | 2018-07-03 | Critical Outcome Technologies, Inc. | Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer |
| EP2318406B1 (en) * | 2008-07-17 | 2016-01-27 | Critical Outcome Technologies, Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
| FR2940652B1 (fr) * | 2008-12-29 | 2011-02-11 | Sanofi Aventis | Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique |
| WO2010076525A1 (fr) | 2008-12-29 | 2010-07-08 | Sanofi-Aventis | Dérivés de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur préparation et leur application en thérapeutique |
| FR2949468B1 (fr) * | 2009-08-28 | 2011-09-30 | Sanofi Aventis | Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique |
| KR20110099786A (ko) | 2008-12-29 | 2011-09-08 | 사노피 | ２-피리딘-２-일-피라졸-３（２ｈ）-온의 유도체, 그의 제조법 및 ｈｉｆ 활성화제로서의 치료 용도 |
| CA2999435A1 (en) | 2010-04-01 | 2011-10-06 | Critical Outcome Technologies Inc. | Compounds and method for treatment of hiv |
| FR2967671A1 (fr) * | 2010-11-24 | 2012-05-25 | Pf Medicament | Complexe de technetium 99m en tant qu'outil de diagnostic in vivo des tumeurs cancereuses |
| CN110818624B (zh) * | 2019-11-22 | 2022-11-22 | 华东理工大学 | 吡啶季铵盐腙类化合物及制备方法与在抗菌或香料缓释中的应用 |
| CN112999369B (zh) * | 2021-03-03 | 2022-02-25 | 江苏元本生物科技有限公司 | 一种her2亲合体放射性核素标记物组合物及其应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4427646A (en) | 1981-04-02 | 1984-01-24 | Research Corporation | Use of radiolabeled peptide derived from crosslinked fibrin to locate thrombi in vivo |
| US4578079A (en) | 1982-08-04 | 1986-03-25 | La Jolla Cancer Research Foundation | Tetrapeptide |
| US4792525A (en) | 1982-08-04 | 1988-12-20 | La Jolla Cancer Research Foundation | Tetrapeptide |
| CA1300608C (en) * | 1985-05-10 | 1992-05-12 | Edward A. Deutsch | 99 mtc (iii) myocardial imaging agents which are non-reducable in vivo |
| GB8624272D0 (en) * | 1986-10-09 | 1986-11-12 | Amersham Int Plc | Cationic complexes of tc-99m |
| US5217705A (en) | 1987-09-25 | 1993-06-08 | Neorx Corporation | Method of diagnosing blood clots using fibrin-binding proteins |
| AU639409B2 (en) | 1987-12-10 | 1993-07-29 | La Jolla Cancer Research Foundation | Conformationally stabilized cell adhesion peptides |
| JPH07110869B2 (ja) * | 1988-03-09 | 1995-11-29 | セ・イ・エス・ビオ・アンテルナシヨナル | 放射性医薬品として使用できる９９ｍＴｃ、１８６Ｒｅまたは１８８Ｒｅの窒化物錯体の製造方法 |
| GB8808414D0 (en) * | 1988-04-11 | 1988-05-11 | Amersham Int Plc | Ligands & cationic complexes thereof with technetium-99m |
| EP0412115A4 (en) | 1988-04-29 | 1991-11-13 | New England Deaconess Hospital Corporation | Hybrid peptides and methods of their use |
| US5002754A (en) * | 1988-06-15 | 1991-03-26 | University Of Cincinnati | Technetium (III/II) imaging agents |
| HUT55799A (en) | 1988-09-29 | 1991-06-28 | Biogen Inc | Process for producing hirudine-like peptides |
| US5066789A (en) * | 1988-09-30 | 1991-11-19 | Neorx Corporation | Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages |
| US5270030A (en) | 1988-12-29 | 1993-12-14 | Bio-Technology General Corp. | Fibrin binding domain polypeptide and method of producing |
| GB8902362D0 (en) * | 1989-02-03 | 1989-03-22 | Amersham Int Plc | Cationic complexes of technetium-99m |
| IL93432A (en) * | 1989-02-24 | 1994-02-27 | Johnson Mathey Inc | Hydrazines and hydrazides, their conjugates with macromolecules and such conjugates labelled with metal ions |
| US5206370A (en) * | 1989-02-24 | 1993-04-27 | Johnson Matthey, Inc. | Certain pyridyl hydrazines and hydrazides useful for protein labeling |
| US4957728A (en) * | 1989-05-19 | 1990-09-18 | University Of Cincinnati | Kit for preparing Tc (III)-99m myocardial imaging agents that are effective in humans |
| US4917879A (en) * | 1989-05-19 | 1990-04-17 | University Of Cincinnati | 99MTC(III) myocardial imaging agents that are effective in humans |
| GB8914020D0 (en) | 1989-06-19 | 1989-08-09 | Antisoma Ltd | Synthetic peptides for use in thrombus detection |
| EP0410537A1 (en) | 1989-07-28 | 1991-01-30 | Merck & Co. Inc. | Fibrinogen receptor antagonists |
| GB8919488D0 (en) * | 1989-08-29 | 1989-10-11 | Amersham Int Plc | New cores for technetium radiopharmaceuticals |
| ZA907743B (en) | 1989-10-03 | 1991-07-31 | Merrell Dow Pharma | Radiolabeled anticoagulant peptides |
| US5086069A (en) | 1990-02-05 | 1992-02-04 | Rorer Pharmaceutical Corporation | Anti-thrombotic peptide and pseudopeptide derivatives |
| US5137877B1 (en) * | 1990-05-14 | 1996-01-30 | Bristol Myers Squibb Co | Bifunctional linking compounds conjugates and methods for their production |
| FR2664166A1 (fr) * | 1990-07-04 | 1992-01-10 | Cis Bio Int | Procede de preparation de complexes nitruro de metaux de transition utilisables comme produits radiopharmaceutiques ou pour la synthese de nouveaux produits radiopharmaceutiques. |
| IL99537A (en) | 1990-09-27 | 1995-11-27 | Merck & Co Inc | Fibrinogen receptor antagonists and pharmaceutical compositions containing them |
| EP0510132B1 (en) * | 1990-09-28 | 1997-05-14 | Neorx Corporation | Polymeric carriers for release of covalently linked agents |
| US5112594A (en) * | 1991-04-04 | 1992-05-12 | Mallinckrodt Medical, Inc. | Kit for preparing a technetium-99m myocardial imaging agent |
| JP2774378B2 (ja) | 1991-02-08 | 1998-07-09 | ダイアテク，インコーポレイテッド | 映像用テクネチウム−９９ｍ標識化ポリペプチド |
| FR2679452B1 (fr) * | 1991-07-22 | 1993-11-12 | Cis Bio International | Produit radiopharmaceutique ayant notamment un tropisme cerebral, comportant un complexe nitruro d'un metal de transition, et son procede de preparation. |
| US5362852A (en) * | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
| ATE329624T1 (de) | 1992-05-21 | 2006-07-15 | Diatide Inc | Technetium-99m markierte peptide zur bilderzeugung von thrombus |
| GB2268494B (en) | 1992-07-08 | 1996-08-21 | Kenneth Francis Prendergast | Imaging compositions |
| FR2698272B1 (fr) * | 1992-11-20 | 1994-12-30 | Cis Bio Int | Procédé de marquage cellulaire au moyen de complexes nitruro-bis (dithiocarbamato)Tc-99m et trousse pour la mise en Óoeuvre de ce procédé. |
| US5879657A (en) * | 1993-03-30 | 1999-03-09 | The Dupont Merck Pharmaceutical Company | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders |
-
1995
- 1995-06-07 US US08/476,296 patent/US5750088A/en not_active Expired - Fee Related
-
1996
- 1996-05-30 IL IL11846896A patent/IL118468A0/xx unknown
- 1996-06-04 HR HR08/476,296A patent/HRP960250A2/hr not_active Application Discontinuation
- 1996-06-06 MY MYPI96002227A patent/MY133974A/en unknown
- 1996-06-07 AR ARP960103028A patent/AR003959A1/es not_active Application Discontinuation
- 1996-06-07 JP JP9501990A patent/JPH11507364A/ja not_active Ceased
- 1996-06-07 AT AT96919289T patent/ATE233241T1/de not_active IP Right Cessation
- 1996-06-07 NZ NZ310799A patent/NZ310799A/xx unknown
- 1996-06-07 BR BR9609003-0A patent/BR9609003A/pt not_active Application Discontinuation
- 1996-06-07 CZ CZ973801A patent/CZ380197A3/cs unknown
- 1996-06-07 ZA ZA9604854A patent/ZA964854B/xx unknown
- 1996-06-07 SI SI9620076A patent/SI9620076B/sl unknown
- 1996-06-07 HU HU9901469A patent/HUP9901469A3/hu unknown
- 1996-06-07 EA EA199800025A patent/EA000742B1/ru not_active IP Right Cessation
- 1996-06-07 EP EP96919289A patent/EP0832068B1/en not_active Expired - Lifetime
- 1996-06-07 PL PL96323995A patent/PL323995A1/xx unknown
- 1996-06-07 CA CA002222183A patent/CA2222183A1/en not_active Abandoned
- 1996-06-07 KR KR1019970709054A patent/KR19990022573A/ko not_active Ceased
- 1996-06-07 DE DE69626392T patent/DE69626392T2/de not_active Expired - Fee Related
- 1996-06-07 SK SK1634-97A patent/SK163497A3/sk unknown
- 1996-06-07 WO PCT/US1996/009766 patent/WO1996040637A1/en not_active Ceased
- 1996-06-07 AU AU61661/96A patent/AU718683B2/en not_active Ceased
- 1996-06-07 ES ES96919289T patent/ES2193245T3/es not_active Expired - Lifetime
- 1996-06-07 MX MX9709126A patent/MX9709126A/es unknown
- 1996-06-07 CN CN96196141A patent/CN1192733A/zh active Pending
- 1996-06-07 EE EE9700313A patent/EE9700313A/xx unknown
-
1997
- 1997-10-23 US US08/956,313 patent/US6015904A/en not_active Expired - Fee Related
- 1997-12-05 NO NO975678A patent/NO975678L/no not_active Application Discontinuation
- 1997-12-05 LT LT97-191A patent/LT4380B/lt not_active IP Right Cessation
-
1998
- 1998-01-28 LV LVP-97-247A patent/LV12044B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI9620076B (sl) | Stabilni reagenti za pripravo radiofarmacevtikov | |
| SI9620044B (sl) | Ternarni radiofarmacevtski kompleksi | |
| AU2023203682B2 (en) | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy | |
| US20230147035A1 (en) | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer | |
| RU2464272C2 (ru) | Арилфосфорамидаты нуклеозида и их применение в качестве противовирусных средств для лечения вирусного гепатита с | |
| ES2972148T3 (es) | Agentes de alta afinidad dirigidos a antígenos de membrana específicos de próstata para la endorradioterapia del cáncer de próstata | |
| EP3609544B1 (en) | Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy | |
| EP3265134B1 (en) | Methods for cell labeling and medical imaging | |
| CA3137963A1 (en) | Prostate-specific membrane antigen (psma) inhibitors as diagnostic and radionuclide therapeutic agents | |
| ES2244608T3 (es) | Complejos de ligandos ternarios utiles como radiofarmacos. | |
| EP4305009A2 (en) | Aliphatic 18f-radiolabeling of a tetrazine precursor | |
| ES2654528T3 (es) | Procedimiento de preparación de un derivado de purina marcado, dicho derivado y sus usos | |
| CN103732563B (zh) | 18f-糖-叶酸类 | |
| US20080260636A1 (en) | Stabilization of radionuclide-containing compositions | |
| ES2985919T3 (es) | Agentes diagnósticos y terapéuticos dirigidos a CXCR4 con selectividad de especie reducida | |
| EP0927049A2 (en) | Labelled elastase inhibitors | |
| JP4723378B2 (ja) | 石灰化組織親和性化合物 | |
| US5820846A (en) | Radiolabeled glucans covalently linked to a radiolabel binding moiety | |
| KR102548998B1 (ko) | 혈전영상을 위한 방사성의약품 및 조성물 | |
| JP2014511338A (ja) | 放射性ヨウ素化グアニジン | |
| NZ792994A (en) | Psma combiner and use thereof | |
| NZ792994B2 (en) | Psma combiner and use thereof | |
| HK1255215B (en) | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy | |
| JP2020524175A5 (2) | ||
| TH1901007253A (th) | บิส-ออกทาไฮโดรฟีแนนทรีนคาร์บอนซาไมด์ และโปรตีนคอนจูเกตของสิ่งเหล่านั้น |